FdaApplication
BLA 761304
Identifiers
- fda_app_no: BLA761304
Properties
| Property | Value |
|---|---|
| applicant_name | Argenx BV |
| application_type | BLA |
| approval_date | 2023-06-20 |
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| VYVGART HYTRULO | EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC | 1008MG | Injection |
| VYVGART HYTRULO | — | 1,000MG/5ML;10,000UNITS/5ML (200MG/2,000UNITS/ML) | Injection |
2 products